Wu Jessie M, Mamelak Adam J, Nussbaum Rachel, McElgunn Patrick S J
School of Medicine, University of Sheffield, UK.
Dermatol Surg. 2005 Aug;31(8 Pt 1):963-5. doi: 10.1097/00042728-200508000-00014.
Chromhidrosis is an uncommon disorder characterized by secretion of colored sweat by apocrine glands, typically localized to the face or axilla. The current treatments available for chromhidrosis are time consuming and frequently ineffective.
Our purpose is to demonstrate a novel approach to the treatment of apocrine chromhidrosis.
We report a case of apocrine chromhidrosis successfully treated with botulinum toxin A (BTX-A; Botox).
BTX-A therapy successfully controlled facial chromhidrosis, and the effects were visible at 19 weeks post-treatment. The therapeutic benefits may be attributed to its inhibitory effects on cholinergic stimulation, adrenergic stimulation, and substance P release, although further studies are necessary to elucidate the precise mechanism of action.
This report demonstrates a new therapeutic approach to patients suffering from chromhidrosis.
色汗症是一种罕见的疾病,其特征是顶泌汗腺分泌有色汗液,通常局限于面部或腋窝。目前可用于色汗症的治疗方法耗时且常常无效。
我们的目的是展示一种治疗顶泌色汗症的新方法。
我们报告一例顶泌色汗症患者成功接受A型肉毒毒素(BTX-A;保妥适)治疗的病例。
BTX-A治疗成功控制了面部色汗症,治疗后19周可见效果。治疗益处可能归因于其对胆碱能刺激、肾上腺素能刺激和P物质释放的抑制作用,尽管需要进一步研究以阐明确切的作用机制。
本报告展示了一种针对色汗症患者的新治疗方法。